Congenital Myotonic Dystrophy
2
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AMO PharmaNC - Durham
3 programs2
TideglusibPhase 2/31 trial
TideglusibPhase 2/31 trial
TideglusibN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AMO PharmaTideglusib
AMO PharmaTideglusib
Clinical Trials (3)
Total enrollment: 132 patients across 3 trials
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Start: Aug 2021Est. completion: Dec 202676 patients
Phase 2/3Recruiting
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Start: Mar 2021Est. completion: Apr 202356 patients
Phase 2/3Completed
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
N/AAvailable
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 132 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.